Clinical studies with megakaryocyte growth and development factor (Mpl-ligand)

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 42-46

  Begley, C Glenn ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; MACROGOL; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT HUMAN THROMBOPOIETIN; RECOMBINANT THROMBOPOIETIN; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MEGAKARYOCYTE; META ANALYSIS; PLOIDY; PRIORITY JOURNAL; RECEPTOR BINDING; STEM CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0030836514     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657498     Document Type: Conference Paper

References (32)

1. Basser R, Clarke K, Fox R, Green M, Cebon J, Marty J, Menchaca D, Tomita D, Begley CG: Randomized double-blind, placebo-controlled phase 1 trial of pegylated megakaryocyte growth and development factor (PEG-rHuMGDF) administered to patients with advanced cancer before and after chemotherapy - early results. Blood 1995; 86 (Suppl. 1): 257a
2. Rasko JEJ, Basser R, O'Malley CJ, Mansfield R, Boyd J, Grigg A, McGrath K, Marty J, Sheridan WP, Hussein S, Berndt MC, Begley CG. In vitro results from a phase I randomized, blinded trial of pegylated megakaryocyte growth and development factor (PEG-rHuMGDF). Blood 1995; 86 (Suppl. 1):497a
3. Basser RL, Rasko JEJ, Clarke K, Cebon J, Green MD, Hussein S, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG: Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348:1279-1281
4. O'Malley CJ, Rasko JJ, Basser RL, McGrath KM, Hopkins W, Grigg AP, Cebon J, Cohen B, Green MD, Fox RM, Berndt MC, Begley CG: Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996; 88:3288-3298
5. Begley CG, Basser R, Clarke K, Rasko J, Green M, Grigg AP, Cebon J, Marty J, Menchaca D, Tomita D, Fox RM: Randomised, double-blind placebo-controlled phase I trial of pegylated megakaryocyte growth and development factor administered to patients with advanced cancer after chemotherapy. Proc Am Soc Clin Onc 1996; 15:719a
6. Fanucchi M, Glaspy J, Crawford J, Ozer H, Giflin R, Tomita D, Menchaca D, Harker L: Safety and biological effects of pegylated megakaryocyte growth and development factor in lung cancer patients receiving carboplatin and paclitaxel: randomised, placebo-controlled phase I study. Proc Am Soc Clin Onc 1996; 15:720a
7. Vadhan-Raj S, Burris H, Benjamin RS, Patel S, Johnston T, Hellman S, Cohen R, Watanabe B, Von Hoff D: Single-dose therapy with recombinant human thrombopoietin (rhTPO) in patients receiving cytotoxic chemotherapy. Proc Am Soc Clin Onc 1996; 15:2010a
8. deBoer R, Fox S, Hopkins W, Casper L, Cheung E, Roskos L, Basser RL, Cebon J: Pharmacodynamics of pegylated megakaryocyte growth & development factor from a phase I study: effects of platelet count on serum levels & clearance. Exp Hematol 1996; 24:744a
9. Basser RL, Rasko JEJ,. Clarke K, Green M, Cebon J, Grigg A, Berndt M, Zalcberg J, Marty J, Menchaca D, Tomita D, Fox R, Begley CG. Pegylated megakaryocyte growth and development factor (PEG-rHuMGDF) enhances the mobilisation of peripheral blood progenitor cells (PBPC) by chemotherapy and filgrastim. Blood 1996; 88 (Suppl. 1):641a
10. Reddy SP, Bueso-Ramos C, Bioko I, Hittelman WN, Vadhan-Raj S: Effects of recombinant human thrombopoietin (rhTPO) on bone marrow megakaryocytes in humans. Blood 1996; 88 (Suppl. 1): 61a
11. Murray LJ, Luens KM, Bruno E, Estrada MF, Cohen RL, Hellman SD. Effects of thrombopoietin on megkaryocytes and progenitor cell populations in bone marrow and peripheral blood of sarcoma patients. Blood 1996; 88 (Suppl. 1):351a
12. Bloedow D, Vadhan-Raj S, Paton V, Johnston T, Yang T, Senn T, Ashby M, Sims P. Pharmacokinetics of recombinant human thrombopoietin (rhTPO) after intravenous administration in cancer patients. Blood 1996; 88 (Suppl. 1):351a
13. Vadhan-Raj S, Patel S, Broxmeyer HE, Bueso-Ramso C, Reddy SP, Papadopolous N, Burgess A, Johnston T, Yang T, Paton V, Hellman S, Benjamin RS. Phase I-II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide(I). Blood 1996; 88 (Suppl. 1):448a
14. Archimbaud E, Ottmann O, Liu Yin JA, Lechner K, Dombret H, Sanz MA, Hermann F, Gruss H, Fenaux P, Ganser A, Heil G, Kanz L, Brugger W, Sims T, Olsen K, Hoelzer D. A randomised, double-blind placebo-controlled study using a PEG-rHuMDF as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia: early results. Blood 1996; 88 (Suppl. 1):447a
15. Basser RL, Rasko JEJ, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Bryne J, Menchaca D, Sheridan WP, Fox RM, Begley CG: Randomised, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; (in press)
16. Kaushansky K and Begley CG: Thrombopoietin: Basic biology and clinical effects. In Hematopoietic Stem Cell Therapy. Eds Ho AD, Champlin RE. Cambridge University Press 1997 in press
17. Kaushansky K, Broudy, VC, Grossmann A, Humes J, Lin N, Ren HP, Bailey MC, Papayannopoulou T, Forstrom JW, Sprugel KH: Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J. Clin. Invest. 1995; 96:1683-1687
18. Grossmann A, Lenox J, Ren HP, Humes JM, Forstrom JW, Kaushansky K, Sprugel KH: Thrombopoietin accelerates platelet, red blood cell and neutrophil recovery in myelosupressed mice, Exp. Hematol. 1996; 24:1238-1246
19. Ulich TR, del Casillo J, Yin S, Swift S, Padilla D, Senaldi G, Bennett L, Shutter J, Bogenberger J, Sun D, Samal B, Shimamoto G, Lee R, Steinbrink R, Boone T, Sheridan WP, Hunt P: Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86:971-6
20. Farese AM, Hunt P, Boone T, MacVittie TJ: Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995: 86:54-9
21. Harker LA: Kinetics of thrombopoiesis. J Clin. Invest 1968; 47:458-465
22. Metcalf D, Begley CG, Johnson GR, Nicola NA, Vadas MA, Lopez AF, Williamson DJ, Wong CG, Clark SC, Wang EA: Biological properties in vitro of a recombinant human granulocyte-macrophage colony stimulating factor. Blood 1986; 67:37-45
23. Begley CG, Lopez AF, Nicola NA, Warren DJ, Vadas MA, Sanderson CJ: Purified colony stimulating factors enhance the survival in vitro of mature human neutrophils and eosinophils in a lineage-specific manner: A rapid sensitive microassay for colony-stimulating factors. Blood 1986; 68:162-166
24. Metcalf D, Begley CG, Williamson DJ, Nice EC, DeLaMarter JF, Merrod JJ, Thatcher D, Schmidz A: Hemopoietic responses in mice injected with purified recombinant murine GM-CSF. Exp Hematol 1987; 15:1-9
25. Debili N, Wendung F, Cosman D, Titeux M, Florindo C, Dusanter-Fourt I, Schooley K, Methis N, Charon M, Nador R, Bettaieb A, Vainchenker W: The mpl receptor is expressed in the megakaryocyte lineage from late progenitors to platelets. Blood 1995; 85:391-401
26. Ezumi Y, Takayama H, Okuma M: Thrombopoietin, c-mpl-ligand, induces tyrosine phosphorylation of Tyk 2, JAK 2, and STAT 3 and enhances agonist-induced aggregation in platelets in vitro. FEBS Letters 1995; 374:48-52
27. Rasko JEJ, Basser RL, Boyd J, Mansfield R, O'Malley CJ, Hussein S, Berndt MC, Clarke K, O'Byrne J, Sheridan WP, Grigg AP, Begley CG: Multilineage mobilisation of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br J Haem 1997; (in press)
28. Begley CG: Human progenitor cell assays. In 'Cell Therapy. Stem cell transplantation, gene therapy, and immunotherapy' Ed's Morstyn G and Sheridan W. Cambridge University Press 1996; pp59-74
29. Dührsen U, Villeval J-L, Boyd J, Kannourakis G, Morstyn G, Metcalf D: Effects of recombinant human granulocyte-colony stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72:2074-81
30. Rasko JEJ, O'Flaherty E, Begley CG: mpl-ligand (MGDF) alone and in combination with SCF promotes proliferation and survival of human megakaryocyte, erythroid and granulocyte/macrophage progenitors. Stem Cells 1997; 15:33-42
31. Deluca E, Sheridan WP, Watson D, Szer J, Begley CG: Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. B J Cancer 1992; 66:893-899
32. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath K, Morstyn G, Fox FM: Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 1992; 339:640-4